SIGLEC1 and hepatocellular carcinoma: As shown in Table 2, the CD169+ Mφ density was associated with a decreased risk of death in HCC (HR 0.561, 95% CI 0.358–0.878, P = 0.011) and GC (HR 0.569, 95% CI 0.343–0.943, P = 0.029) patients.